Want to see TSE:OVAT full AI Analyst Report?
OVAT Stock Chart & Stats
C$0.03
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.03
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.02 - C$0.05
Previous CloseN/A
Volume54.36K
Average Volume (3M)1.19K
Market Cap
C$1.15M
Enterprise ValueC$855.55K
Total Cash (Recent Filing)C$13.22K
Total Debt (Recent Filing)C$292.14K
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Nov 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding38,441,680
10 Day Avg. Volume0
30 Day Avg. Volume1,188
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)-0.98
Price to Sales (P/S)20.98
P/FCF Ratio-18.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Transdermal TechnologyA proprietary transdermal delivery approach can differentiate Ovation’s topical products from conventional formulations and provide a platform for multiple skin-related applications. If commercialization progresses, this technology-centered model may support repeat product development and longer-term competitive positioning.
Improved Cash-Burn ControlMaterially lower cash burn indicates some cost containment and better operating discipline compared with earlier periods. Although cash generation remains negative, maintaining this improvement could extend financial runway, reduce funding pressure, and create more time for products to gain commercial traction.
Focused Topical Product PlatformA focused portfolio spanning personal care and skin health gives Ovation a defined commercial identity rather than an unrelated collection of activities. Concentrating development and marketing around topical products may help prioritize resources and build capabilities within a consistent product category.
Bears Say
Persistent UnprofitabilityPersistent operating and net losses show that the business has not yet established a profitable operating model. Continued losses can restrict reinvestment, weaken financial resilience, and make future growth dependent on outside capital unless revenue and margins improve sustainably.
Negative Equity And Financing RiskNegative equity is a significant balance-sheet weakness because liabilities exceed the recorded asset base and financial flexibility is limited. Combined with existing debt and ongoing losses, this increases recapitalization and dilution risk if the company needs funding to continue operations.
Negative Cash GenerationConsistently negative operating and free cash flow means the business does not currently fund itself through operations. Even with improved burn, ongoing cash deficits can require external financing, constrain investment in commercialization, and expose shareholders to funding or dilution pressure.
Ovation Science News
OVAT FAQ
What was Ovation Science Inc’s price range in the past 12 months?
Ovation Science Inc lowest stock price was C$0.01 and its highest was C$0.05 in the past 12 months.
What is Ovation Science Inc’s market cap?
Ovation Science Inc’s market cap is C$1.15M.
When is Ovation Science Inc’s upcoming earnings report date?
Ovation Science Inc’s upcoming earnings report date is Nov 30, 2026 which is in 31 days.
How were Ovation Science Inc’s earnings last quarter?
Ovation Science Inc released its earnings results on Aug 11, 2026. The company reported -C$0.004 earnings per share for the quarter.
Is Ovation Science Inc overvalued?
According to Wall Street analysts Ovation Science Inc’s price is currently Overvalued.
Does Ovation Science Inc pay dividends?
Ovation Science Inc does not currently pay dividends.
What is Ovation Science Inc’s EPS estimate?
Ovation Science Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ovation Science Inc have?
Ovation Science Inc has 38,441,680 shares outstanding.
What happened to Ovation Science Inc’s price movement after its last earnings report?
Ovation Science Inc reported an EPS of -C$0.004 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Ovation Science Inc?
Currently, no hedge funds are holding shares in TSE:OVAT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ovation Science Inc
Ovation Science Inc. specializes in the creation of cannabis and hemp-based products, distributed across Canada, the United States, and Mexico. A cornerstone of its offerings is Invisicare, a patented drug delivery technology employed in topical and transdermal skincare formulations. This system integrates hemp seed oil and cannabis, underpinning the company's Ovation and BASKiN brands. Additionally, Ovation Science provides a diverse product portfolio including Invibe MD for CBD-infused health and wellness, ARLO CBD for skincare, and DermSafe for hand sanitizers. The company possesses sublicenses for its cannabis product lines and utilizes its Lighthouse initiative to engage with licensed dispensaries throughout the United States. Founded in 2017, Ovation Science Inc. is based in Vancouver, Canada.
Technical Analysis
Willow Biosciences Inc
―
MediPharm Labs
―
Nextleaf Solutions
―
Vext Science
―
BioNxt Solutions
―